127 related articles for article (PubMed ID: 19684446)
1. Economic evaluation of human papillomavirus vaccination in developed countries.
Brisson M; Van de Velde N; Boily MC
Public Health Genomics; 2009; 12(5-6):343-51. PubMed ID: 19684446
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment.
Qendri V; Bogaards JA; Baussano I; Lazzarato F; Vänskä S; Berkhof J
Lancet Public Health; 2020 Nov; 5(11):e592-e603. PubMed ID: 33120045
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus vaccination for boys.
Quinn S; Goldman RD
Can Fam Physician; 2015 Jan; 61(1):43-6. PubMed ID: 25756144
[TBL] [Abstract][Full Text] [Related]
4. Recent economic evaluation of 1-dose HPV vaccination uses unsupported assumptions.
Burger E; Baussano I; Kim JJ; Laprise JF; Berkhof J; Schiller JT; Canfell K; Prem K; Brisson M; Jit M; Barnabas RV
Vaccine; 2023 Apr; 41(16):2648-2649. PubMed ID: 35941035
[No Abstract] [Full Text] [Related]
5. Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9-10, 2009.
Craig BM; Brisson M; Chesson H; Giuliano AR; Jit M
Clin Ther; 2010 Aug; 32(8):1546-64. PubMed ID: 20728767
[TBL] [Abstract][Full Text] [Related]
6. The cost effectiveness of human papillomavirus vaccines: a systematic review.
Seto K; Marra F; Raymakers A; Marra CA
Drugs; 2012 Mar; 72(5):715-43. PubMed ID: 22413761
[TBL] [Abstract][Full Text] [Related]
7. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
8. Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries.
Simonella L; Canfell K
Vaccine; 2015 Jan; 33(1):34-51. PubMed ID: 25171843
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review.
Fesenfeld M; Hutubessy R; Jit M
Vaccine; 2013 Aug; 31(37):3786-804. PubMed ID: 23830973
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Jit M; Brisson M; Portnoy A; Hutubessy R
Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
[TBL] [Abstract][Full Text] [Related]
11. Public Health Genomics: Time to Sharpen the Focus.
McBride CM; Roberts JS; Knerr S; Guan Y
Public Health Genomics; 2023; 26(1):171-176. PubMed ID: 37729876
[No Abstract] [Full Text] [Related]
12. Knowledge, Perceptions and Attitudes Toward HPV Vaccination: A Survey on Parents of Girls Aged 11-18 Years Old in Greece.
Naoum P; Athanasakis K; Zavras D; Kyriopoulos J; Pavi E
Front Glob Womens Health; 2022; 3():871090. PubMed ID: 35783121
[TBL] [Abstract][Full Text] [Related]
13. HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control.
Canfell K; Kim JJ; Kulasingam S; Berkhof J; Barnabas R; Bogaards JA; Campos N; Jennett C; Sharma M; Simms KT; Smith MA; Velentzis LS; Brisson M; Jit M
Papillomavirus Res; 2019 Dec; 8():100184. PubMed ID: 31505258
[TBL] [Abstract][Full Text] [Related]
14. HPV-vaccination and cancer cervical screening in 53 WHO European Countries: An update on prevention programs according to income level.
Altobelli E; Rapacchietta L; Profeta VF; Fagnano R
Cancer Med; 2019 May; 8(5):2524-2534. PubMed ID: 30993902
[TBL] [Abstract][Full Text] [Related]
15. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
Brisson M; Bénard É; Drolet M; Bogaards JA; Baussano I; Vänskä S; Jit M; Boily MC; Smith MA; Berkhof J; Canfell K; Chesson HW; Burger EA; Choi YH; De Blasio BF; De Vlas SJ; Guzzetta G; Hontelez JAC; Horn J; Jepsen MR; Kim JJ; Lazzarato F; Matthijsse SM; Mikolajczyk R; Pavelyev A; Pillsbury M; Shafer LA; Tully SP; Turner HC; Usher C; Walsh C
Lancet Public Health; 2016 Nov; 1(1):e8-e17. PubMed ID: 29253379
[TBL] [Abstract][Full Text] [Related]
16. Tumour virus vaccines: hepatitis B virus and human papillomavirus.
Stanley M
Philos Trans R Soc Lond B Biol Sci; 2017 Oct; 372(1732):. PubMed ID: 28893935
[TBL] [Abstract][Full Text] [Related]
17. Ecological validity of cost-effectiveness models of universal HPV vaccination: a protocol for a systematic review.
Favato G; Noikokyris E; Vecchiato R
Syst Rev; 2017 Jan; 6(1):17. PubMed ID: 28118846
[TBL] [Abstract][Full Text] [Related]
18. Including males in Canadian human papillomavirus vaccination programs: a policy analysis.
Shapiro GK; Perez S; Rosberger Z
CMAJ; 2016 Sep; 188(12):881-886. PubMed ID: 27114488
[No Abstract] [Full Text] [Related]
19. Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines.
Brotherton JM; Jit M; Gravitt PE; Brisson M; Kreimer AR; Pai SI; Fakhry C; Monsonego J; Franceschi S
Int J Cancer; 2016 Aug; 139(3):510-7. PubMed ID: 26916230
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
